Axsome Therapeutics, Inc. AXSM

Axsome Therapeutics, Inc. comes into the 2026-06-19 daily file with a useful split-screen: the supplied SEC financial rail shows $191.2 million of revenue from contract with customer, excluding assessed tax, for the 10-Q period ending 2026-03-31, while the same period shows net income attributable to parent of negative $64.5 million and diluted EPS of negative $1.26. That is the centre of the story: commercial scale exists, but profitability has not arrived on this evidence.

AXSM is an equity tied to Axsome Therapeutics, Inc., a product company in the therapeutic market rather than a wrapper or commodity. The supplied scout evidence does not provide a product launch, approval decision, label detail, sales split, image, or pipeline update. What it does provide is the operating frame through filings: revenue, R&D spending, inventory, cash, liabilities and a recent governance item in an SEC 8-K.

The latest filed financial facts supplied are from the 10-Q period ending 2026-03-31. Revenue from contract with customer, excluding assessed tax, was $191.2 million. Operating loss was negative $63.4 million. Net income attributable to parent was negative $64.5 million. Research and development expense was $52.7 million. Cash and cash equivalents were $305.1 million. Assets were $713.6 million, liabilities were $659.0 million, and stockholders' equity attributable to parent was $54.6 million. Net cash used in operating activities was negative $20.7 million, inventory was $31.5 million, and diluted weighted average shares outstanding were 51.2 million.

The chart rail is not supplied in the source list, so this file does not invent candles, levels, moving averages or price behaviour. The market mechanism that can be described from the evidence is simpler: AXSM is being judged through SEC filings, operating losses, cash consumption, R&D intensity, inventory, and public ownership or governance filings listed through SEC EDGAR.

What changed on the public document rail is a run of SEC items in June. The source list names multiple Form 4 filings on 2026-06-10 and 2026-06-11, a Form 144 on 2026-06-11, and an Official SEC EDGAR 8-K dated 2026-06-09. The supplied 8-K excerpt says the Compensation Committee of the Board approved the adoption of an Axsome Therapeutics, Inc. item, but the excerpt does not provide the full plan terms here. That makes the filing relevant as governance evidence, not as proof of a drug approval, commercial milestone or earnings change.

The cleanest reading is that AXSM's current evidence file is financial and administrative rather than promotional. It shows meaningful revenue, continued losses, a cash balance large enough to anchor the near-term story, and a set of June SEC filings that should be treated as named public developments within their limits. A deeper file would need source-backed product detail, trial or approval evidence, sales mix, guidance, chart route data, or full filing terms beyond the excerpt supplied.